Systimmune
A Principal Scientist at SystImmune leads the development of immunohistochemistry (IHC) companion diagnostics for oncology drug programs, ensuring regulatory compliance and clinical implementation.
Headquarters
Redmond, Washington, United States
Company Size
11-50 employees
Founded
2014
SystImmune is a Redmond, WA–based biopharmaceutical company developing bi‑specific and multi‑specific antibodies and antibody‑drug conjugates (ADCs) to treat cancer. Its mission is to create biologics that both directly attack tumors and activate the immune system to enhance anti‑tumor responses, using proprietary protein‑engineering and antibody‑discovery platforms. A multidisciplinary team across the U.S. and China focuses on rapid, cost‑efficient clinical development. SystImmune is a member of the Biokin Pharmaceutical group and partners with Bristol Myers Squibb and OrbiMed, and it is seeking additional collaborators to develop and commercialize its therapies worldwide.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Systimmune.
5% above the average for this role
Research Technician, Biobank and Histology Core - IHC Division
Memorial Sloan Kettering Cancer Center
IHC Technologist
CellNetix Pathology and Laboratories
Regulatory Affairs Consultant (IVD/CDx)
MDC Associates
IHC Histology Technician II
Sunrise Medical Laboratories
Associate Director, RC Discovery – Immunohistochemistry (IHC)
American Association of Physicists in Medicine
IHC Lab Assistant
HistoWiz